Illustration: Maura Kearns/Axios
Eli Lilly agreed to buy privately held cell therapy and circular RNA biotech Orna Therapeutics in a deal worth up to $2.4 billion.
Why it matters: Lilly is the latest Big Pharma company to acquire a circular RNA startup as the sector heats up.
